Biora Therapeutics, Inc. Total Assets
Biora Therapeutics, Inc. total assets. Based on the latest financial reports, Biora Therapeutics, Inc. (BIORQ) holds total assets worth $14.51 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BIORQ stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Biora Therapeutics, Inc. (2018–2023)
Total assets of Biora Therapeutics, Inc. from 2018 to 2023. This chart illustrates how Biora Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See BIORQ live share price for real-time trading data and today's change.
Biora Therapeutics, Inc. - Asset Composition Analysis
Biora Therapeutics, Inc. Total Assets Breakdown (December 2023)
Biora Therapeutics, Inc. total assets breakdown as of December 2023. Biora Therapeutics, Inc.'s total assets of $14.51 Million consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.7% |
| Accounts Receivable | $830.00K | 2.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $6.07 Million | 19.5% |
Asset Composition Trend (2018–2023)
This chart illustrates how Biora Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Biora Therapeutics, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biora Therapeutics, Inc.'s current assets represent 61.1% of total assets in 2023, a decrease from 76.4% in 2018.
- Cash Position: Cash and equivalents constituted 48.7% of total assets in 2023, up from 42.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 9.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 19.5% of total assets.
Biora Therapeutics, Inc. Competitors by Total Assets
Key competitors of Biora Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Biora Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.28 | 0.76 |
| Quick Ratio | 0.05 | 0.28 | 0.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-114.56 Million | $-50.30 Million | $-22.08 Million |
Biora Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Biora Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -41.7% |
| Total Assets | $31.21 Million |
| Market Capitalization | $994.99K USD |
Valuation Analysis
Below Book Valuation: The market values Biora Therapeutics, Inc.'s assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biora Therapeutics, Inc.'s assets decreased by 41.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biora Therapeutics, Inc. (2018–2023)
The table below shows the annual total assets of Biora Therapeutics, Inc. from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $31.21 Million | -41.68% |
| 2022-12-31 | $53.52 Million | -50.82% |
| 2021-12-31 | $108.84 Million | -29.53% |
| 2020-12-31 | $154.44 Million | +51.82% |
| 2019-12-31 | $101.73 Million | -12.60% |
| 2018-12-31 | $116.40 Million | -- |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more